Pyridam Farma Bukukan Kerugian Rp 85,22 Miliar pada Tahun 2023 - KONTAN
| PYFA Stock | IDR 236.00 8.00 3.28% |
About 61% of Pyridam Farma's investor base is looking to short. The analysis of current outlook of investing in Pyridam Farma Tbk suggests that many traders are alarmed regarding Pyridam Farma's prospects. Pyridam Farma's investing sentiment shows overall attitude of investors towards Pyridam Farma Tbk.
Pyridam |
Pyridam Farma Bukukan Kerugian Rp 85,22 Miliar pada Tahun 2023 KONTAN
Read at news.google.com
 |
Pyridam Farma Fundamental Analysis
We analyze Pyridam Farma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pyridam Farma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pyridam Farma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Profit Margin
Profit Margin Comparative Analysis
Pyridam Farma is currently under evaluation in profit margin category among its peers. Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Pyridam Farma Tbk Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pyridam Farma stock to make a market-neutral strategy. Peer analysis of Pyridam Farma could also be used in its relative valuation, which is a method of valuing Pyridam Farma by comparing valuation metrics with similar companies.
Peers
Pyridam Farma Related Equities
| MRAT | Mustika Ratu | 1.94 | ||||
| MERK | Merck Tbk | 0.28 | ||||
| INAF | Indofarma Tbk | 0.00 | ||||
| KAEF | Kimia Farma | 0.78 | ||||
| TSPC | Tempo Scan | 0.79 |
Other Information on Investing in Pyridam Stock
Pyridam Farma financial ratios help investors to determine whether Pyridam Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pyridam with respect to the benefits of owning Pyridam Farma security.